ESC Congress

Heart
#Cardiovascular disease #ESC Congress #IsomAb #Review

Landmark safety data support therapeutic angiogenesis

Safety evidence announced at the ESC Congress 2026 by Isomab has reinforced the potential of a new class of therapies designed to promote blood vessel growth as a disease-modifying approach for coronary artery disease (CAD).   The systematic review of clinical trial data evaluating growth factor approaches, spanning… Read More

#News

Human heart
#AstraZeneca #Clinical trials #ESC Congress #Heart failure

AstraZeneca provides updates at the ESC Congress

At this year’s annual European Society of Cardiology conference (ESC Congress 2024), which took place from 30 August – 2 September, AstraZeneca presented research that spans 38 abstracts, focusing on unmet need in heart failure (HF) and transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), and other chronic diseases.  Data highlights… Read More

#News